Synergistic Use of Novel Technological Advances in Burn Care Significantly Reduces Hospital Length of Stay Below Predicted: A Case Series.
Habib AblaElizabeth BrownAlan PangMaria BatchinskyAkshay RaghuramAmanda VenableJennifer KeseySharmila DissanaikeDeepak BharadiaJohn GriswoldPublished in: Journal of burn care & research : official publication of the American Burn Association (2022)
Length of stay is an important metric in healthcare systems, primarily because it reflects the cost of care provided. In the United States, as in many countries, inpatient hospital stays are significantly more expensive than outpatient care across all healthcare conditions,1 so earlier discharge and transition to outpatient care is crucial to help control the ever-increasing cost of healthcare. In burn patients, length of stay has traditionally been estimated at 1 day per 1% total body surface area of burn. This estimation was first described in a round table discussion in 1986.2 However, since that time there has been significant evolution in the quality of care available to burn patients, in both the operating room and ICU. The use of new harvesting techniques, synthetic dermal substitution, and autologous epidermal skin cell suspension are allowing large, deep burns to be excised and covered in much quicker time frames than historically were possible. Examples include the skin harvesting and wound debridement device for grafting and excision, biodegradable temporizing matrix as a fully synthetic dermal template, and regenerative epidermal suspension concerning cell harvesting. Although these modalities can all be used separately, we believe that using them in conjunction has allowed us to shorten the length of stay in patients with severe partial and full-thickness burns. We present an initial case series of three patients with anticipated hospital lengths of stay of 54.5, 55, and 51 days, who were ready for discharge in 37, 35, and 43 days, respectively.
Keyphrases
- healthcare
- wound healing
- palliative care
- end stage renal disease
- quality improvement
- cell therapy
- ejection fraction
- stem cells
- newly diagnosed
- chronic kidney disease
- affordable care act
- mesenchymal stem cells
- mental health
- pain management
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- bone marrow
- intensive care unit
- mass spectrometry
- health insurance
- early onset
- adverse drug
- patient reported
- soft tissue
- tandem mass spectrometry
- simultaneous determination